J Korean Med Sci.  2021 Apr;36(15):e110. 10.3346/jkms.2021.36.e110.

Early Safety Monitoring of COVID-19 Vaccines in Healthcare Workers

• Song JY
• Cheong HJ
• Kim SR
• Lee SE
• Kim SH
• Noh JY
• Yoon YK
• Choi WS
• Park DW
• Sohn JW
• Kim WJ
• Kim MJ

• KMID: 2515043
• DOI: http://doi.org/10.3346/jkms.2021.36.e110

Abstract

Hospital-based surveillance for adverse events was conducted on healthcare workers after they received the first dose of coronavirus disease 2019 (COVID-19) vaccine. Among the two new platform vaccines (messenger RNA- and adenoviral vector-based vaccines), the rates of systemic adverse events were significantly higher among adenovirus-vectored vaccine recipients. Fatigue (87.6% vs. 53.8%), myalgia (80.8% vs. 50.0%), headache (72.0% vs. 28.8%), and fever (≥ 38.0°C, 38.7% vs. 0%) were the most common adverse events among adenovirus-vectored vaccine recipients, but most symptoms resolved within 2 days. Both types of COVID-19 vaccines were generally safe, and serious adverse events rarely occurred.

Keyword

COVID-19; Vaccine; Safety; Adverse Event; Surveillance

Reference

1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397(10269):99–111. PMID: 33306989.

2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020; 383(27):2603–2615. PMID: 33301246.

3. Ministry of Health and Welfare (MOHW). Coronavirus disease-19 vaccination. Updated 2021. Accessed March 23, 2021. http://ncv.kdca.go.kr/.

4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021; 396(10267):1979–1993. PMID: 33220855.

5. Brighton Collaboration. Priority list of adverse events of special interest: COVID-19. Updated 2021. Accessed March 23, 2021. https://brightoncollaboration.us/priority-list-aesi-covid/.

6. Medicines and Healthcare products Regulatory Agency (MHRA). Coronavirus vaccine - weekly summary of Yellow Card reporting. Updated 2021. Accessed March 31, 2021. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting.